The launch represents the first commercial application in the European Union for the new treatment. Hepatitis C is the leading cause of liver disease in Western Europe and the most common reason for liver transplant. This breakthrough combination therapy has proven to be substantially more effective than previous treatment options.
Ribavirin is a synthetic nucleoside analog with broad-spectrum antiviral activity.
It also markets the combination therapy in Canada. ICN manufactures and markets a broad range of prescription and non-prescription pharmaceuticals and biotechnology research products in over 90 countries. The company employs some 13,000 people worldwide. ICN has operations in North and Latin America, Western, Central and Eastern Europe, and the Pacific Rim countries. No part of this publication may be redistributed in any form without prior permission.